title: Neutrophilic eccrine hidradenitis associated with decitabine.
authors.forename: Esther S
authors.initials: ES
authors.lastname: Ng
authors.forename: Derrick C
authors.initials: DC
authors.lastname: Aw
authors.forename: Kong Bing
authors.initials: KB
authors.lastname: Tan
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Poon
authors.forename: Eng Soo
authors.initials: ES
authors.lastname: Yap
authors.forename: Te Chih
authors.initials: TC
authors.lastname: Liu
authors.forename: Lip-Kun
authors.initials: LK
authors.lastname: Tan
authors.forename: Wee Joo
authors.initials: WJ
authors.lastname: Chng
authors.forename: Liang-Piu
authors.initials: LP
authors.lastname: Koh
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D003622:Dapsone / Q000627:therapeutic use; D000077209:Decitabine; D005260:Female; D016575:Hidradenitis / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D003622:Dapsone; D011239:Prednisolone; D001374:Azacitidine